abstract |
The use of a cancer disease modifying antibody (CDMAB) 78D-33-11A, to treat a tumor in humans and methods to isolate and identify cancer cells that express a CD63 antigenic portion. Monoclonal antibody 78D-33-11A (ATCC accession number PTA-4890), which binds a CD63 antigenic portion, is cytotoxic to cancer cells that express the antigenic portion. The monoclonal antibody 78D-33-11A is useful to slow the disease progression of a human tumor. |